Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours

European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society
Cora N SternbergMichelle Holland

Abstract

The oral fluoropyrimidine capecitabine (Xeloda) delivers 5-FU to the tumour site, thereby limiting the side effects and other complications associated with intravenous (i.v.) 5-FU. As an oral drug, capecitabine is preferred to 5-FU by many patients as it can be conveniently taken at home. In first-line metastatic colorectal cancer (MCRC), capecitabine results in superior response rates and equivalent progression-free and overall survival compared with i.v. 5-FU/LV. There is also increasing evidence for replacing i.v. 5-FU with capecitabine in combination with other anticancer agents (e.g. oxaliplatin and irinotecan) in MCRC and in the adjuvant treatment of early stage colon cancer. In anthracycline-pretreated metastatic breast cancer (MBC), adding capecitabine to docetaxel improves survival, time to progression (TTP) and response rates beyond docetaxel. Single-agent capecitabine is also effective in pretreated MBC and is a promising first-line therapy. Capecitabine has a favourable safety profile, the most frequent adverse events being hand-foot syndrome, stomatitis and diarrhoea. Because capecitabine is orally administered, it is possible to intervene promptly with dose interruption/reduction to resolve adverse events without ...Continue Reading

References

Jan 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H J Schmoll
Dec 16, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M MiwaH Ishitsuka
Mar 11, 1999·Cancer Chemotherapy and Pharmacology·B ReignerE Weidekamm
Nov 18, 2000·Investigational New Drugs·D R Budman
Apr 5, 2001·Clinical Pharmacokinetics·B ReignerE Weidekamm
Apr 6, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C TwelvesUNKNOWN Xeloda Colorectal Cancer Study Group
Mar 29, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Markus M BornerArnaud D Roth
Jun 12, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J CassidyUNKNOWN Capecitabine Colorectal Cancer Study Group
Jun 18, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joyce O'ShaughnessyRobert Leonard
Sep 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jürgen DunstStefan Frings
Mar 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Werner ScheithauerDieter Depisch
May 2, 2003·Expert Review of Anticancer Therapy·Virginia G Kaklamani, William J Gradishar
May 24, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H BonnefoiM Piccart
Jul 26, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P ReichardtH J Lück
Sep 5, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M ZeuliF Cognetti
Sep 5, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M TewesU Vanhoefer
Sep 27, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Melina Verso, Giancarlo Agnelli
Dec 11, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard M GoldbergSteven R Alberts
Feb 14, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P FumoleauM Namer
Apr 10, 2004·Cancer·Ada H BraunPeter Preusser
Jun 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jim CassidyEduardo Díaz-Rubio

❮ Previous
Next ❯

Citations

Mar 14, 2007·European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society·Joan D Webster-GandyKaren Harrold
Mar 26, 2014·Journal of Clinical Pharmacy and Therapeutics·L Q ZhuY Thian
Sep 3, 2004·European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society·Hilde MarséSonia Valverde
Sep 3, 2004·European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society·Yvonne Lassere, Paulo Hoff
Aug 25, 2006·Clinical Journal of Oncology Nursing·Deborah T Berg
Feb 1, 2007·The Nurse Practitioner·Diane P Doyle, Constance Engelking
Apr 18, 2008·Anti-cancer Drugs·Muhammad Wasif SaifKostas N Syrigos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Related Papers

European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society
Bonnie-Mae Gerbrecht, Tuija Kangas
European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society
Hilde MarséSonia Valverde
Annals of Oncology : Official Journal of the European Society for Medical Oncology
W ScheithauerX-ACT Study Group
© 2021 Meta ULC. All rights reserved